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Abstract
Several lines of evidence support a role of immune mechanisms in the
pathogenesis of chronic heart failure (CHF). Proinflammatory cytokines
(interleukin-1, -2, -6, and tumor necrosis factor) and chemokines are involved
in cardiac depression and in the progression of heart failure. Other compo-
nents believed to be relevant to the pathogenesis of CHF are adhesion mol-
ecules, autoantibodies, nitric oxide (NO), and endothelin-1. The origin of the
immune activation in patients with CHF is still unknown, however two
hypotheses have been proposed on the basis of experimental and clinical
data. One suggests that the bowel wall edema leads to bacterial transloca-
tion with subsequent endotoxin release and immune activation. The second
suggests that the heart in CHF is the main source of cytokines, as is shown
by the fact that TNFα is produced by the failing myocardium but not by a
normal one. No single source of cytokine production (gut or heart) seems
sufficient to fully explain the multiple organ involvement and the systemic
inflammation of CHF, which is probably related to systemic hypoxia,
a potent stimulus for activation of the immune system and for cytokine
production. The effort to define the immune system’s role has opened new
perspectives of therapeutic strategies, such as anti-cytokine drugs, to treat
CHF.
Index Entries: Heart failure; cytokines; autoantibodies; adhesion mol-
ecules; complement; endothelin.
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Introduction
Chronic heart failure (CHF) is a syndrome characterized by
fatigue, shortness of breath, congestion, and cachexia, symptoms
related to the inadequate perfusion of tissue during exertion and often
to the retention of fluid. Its primary cause is an impairment of the
heart’s ability to fill or empty the left ventricle properly (1). Vascular
and neuroendocrine mechanisms are important contributors to the
abnormalities in regional blood flow, renal sodium retention, and
pulmonary congestion that lead to symptoms. Activation of the renin-
angiotensin system and the sympathetic nervous system contribute to
the structural changes in the heart and peripheral vasculature that lead
to the progressive remodeling of the left ventricle in CHF (2–4).
After the earliest report of high serum levels of tumor necrosis fac-
tor-α (TNF-α) in CHF patients (5), several studies have shown a role of
immune mechanisms in the pathogenesis of CHF (6). In particular,
proinflammatory cytokines (interleukin-1 [IL-1], IL-2, IL-6, and TNF)
are involved in cardiac depression and in the progression of the heart
failure. Chemokines, which are cytokines with chemotactive activity
such as IL-8, are also involved in cardiac dysfunction and considered
markers of tissue damage (7). Other components believed to be relevant
to the pathogenesis of CHF are adhesion molecules, autoantibodies,
nitric oxide (NO), and endothelin-1 (8). The effort to define the immune
system’s role was stimulated by the possibility of using new therapeu-
tic strategies, such as anti-cytokine drugs, to treat CHF.
Tumor Necrosis Factor
The important role of tumor necrosis factor (TNF) in heart failure
has first postulated by Levine et al. in 1990 (5), who found high circu-
lating levels of TNF-α in CHF. Patients with the highest values were
more cachectic and had more advanced heart failure, as evidenced by
their high plasma renin activity and low serum sodium concentrations.
Subsequent investigators confirmed the high plasma levels of TNF in
CHF and reported a relation between circulating levels of TNF and
clinical features of the disease (9–14). A study on myocardial biopsies
found TNF-α was high in the myocardium of CHF patients, especially
in end stages, and plasma levels of TNF-α correlated with mRNA
expression in the myocardium (15). Thus plasma levels of TNF-α may
also serve as a marker of myocardial cytokine activation. Measures that
improved heart failure were accompanied by a decrease in circulating
TNF (16).
Experimental studies in animals showed that TNF and the other
proinflammatory cytokines had a direct negative inotropic effect (17),
Heart Failure and Immunity 327
Clinical Reviews in Allergy and Immunology Volume 23, 2002
probably through a myocardial nitric oxide synthase (NOS) (18). The
high TNF concentrations affect NO-mediated vasodilatation in CHF
(12). These high TNF-α levels were also associated with increased
pulmunary vascular permeability, left ventricular remodeling, and the
development of dilated cardiomyopathy (19–21).
TNF-α can induce wasting and apoptosis in skeletal muscle, as
shown in animals (22,23). TNF-α levels are very high in cachectic CHF
patients and have been found to be the strongest predictors of weight
loss (24). Thus TNF-α is potentially responsible for many of the clinical
features of CHF.
TNF-α exerts its cellular actions by two specific receptors, TNFR1
and TNFR2, which are present in all cells except red blood cells (25). In
1995, Ferrari et al. reported that it was essential to measure these recep-
tors to assess the activation of TNF in CHF. They found that the soluble
forms of both TNFR1 and TNFR2 were increased and that they might
inhibit the cytotoxicity of TNF-α because there was a discrepancy
between the antigenic and biological activity of TNF-α (26). Although
the roles of these receptors are still not clear, it has been evidenced that
both molecules have prognostic value. Soluble TNFR2 levels are inde-
pendently correlated with poor short-term prognosis (26) and are a
good predictor of mortality (27). Soluble TNFR1 was found to be the
strongest and most accurate prognosticator, independent of established
markers of CHF severity (28).
Interleukin-1
The effect of IL-1 on cardiac function is controversial. It acts as a
growth factor for fibroblasts, lymphocytes, and smooth muscle cells
(29,30), but it also exerts a potent anti-proliferative effect on cardiac
fibroblasts although it induces cardiac myocyte hypertrophy (31).
IL-1ß increases in the failing heart (32) and depresses myocardial con-
tractility by stimulating NOS (33). Moreover, it inhibits cardiac myo-
cyte beta-adrenergic responsiveness (34).
Interleukin-6
IL-6 plasma levels are high in CHF (14,35,36) and have been asso-
ciated with a worse New York Heart Association (NYHA) functional
class and related to the severity of disease and hospital mortality (37,38).
The mechanism by which IL-6 exerts its deleterious effects is not
known, but there is initial evidence that it is involved in the develop-
ment of ventricular hypertrophy by an interaction with a receptor
known as glycoprotein 130 (gp130), expressed on the cardiac myocyte
(39). IL-6 levels are high in patients with left ventricular dysfunction
even in the absence of the clinical syndrome of CHF (40) and are con-
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sidered a prognostic marker associated with poor prognosis in CHF
(41,42). Although in the left ventricular dysfunction trial (SOLVD), no
relation was found between IL-6 plasma levels and survival (14), the
VEST trial on 1200 patients found that IL-6, like TNF and TNF recep-
tors, were an independent predictors of mortality in patients with
CHF (27).
Interleukin-2
IL-2 has negative inotropic effects in vitro (17) and intravenous
high-dose IL-2 causes important cardiovascular side effects such as
hypotension, fluid retention, arrhythmias, and myocardial ischemia
(43). Although there are some divergent reports (44), IL-2 is usually
high in CHF patients, confirming activation of cellular components of
the immune system (12). IL-2 exerts its cellular function through its
receptor IL-2R, induced by T-cell activation. A study published in 1993
(45), described increased concentrations of soluble IL-2 receptors
(indicative of T-lymphocyte activation), soluble CD8 and neopterin (a
product of activated macrophages), and detectable interferon-γ (IFN-γ)
in some patients with CHF, concluding there was a cellular immune
activation. IL-2 and IL-2R are both correlated with the severity of CHF
(35,46). The increase of soluble IL-2 receptors (sIL-2R) levels in CHF
has been confirmed, with an increase of the soluble antiapoptotic mol-
ecule sFas (47). The high level of sIL2-R was positively correlated with
the increase of sFas, suggesting a relationship between programmed
myocyte cell death and activation of the immune system in this situa-
tion (47).
Chemokines
Activation and migration of leukocytes to areas of myocardial
inflammation appear to be important in CHF (48). Chemokines are
potent chemoattractants of monocytes and lymphocytes and can influ-
ence other functions of these cells, such as generation of cytokines and
reactive oxygen species (ROS). Their importance in cardiac damage and
cardiac muscle dysfunction is illustrated by some experimental find-
ings (49–51). In 1998, Aukrust et al. reported for the first time in patients
with CHF high levels of chemokines, particularly the macrophage
chemoattractant protein-1 (MCP-1), macrophage inflammatory protein-
1 alpha (MIP-1α), and RANTES (Regulated on Activation Normally
T-cell Expressed and Secreted).
In patients with CHF, the increases of MCP-1, MIP-1α, and
RANTES seemed to be caused by higher release from monocytes and
also from CD3-leukocytes and platelets (48). Analysis of three other
chemokines, IL-8, growth-regulated oncogene alpha (GRO α) and epi-
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thelial neutrophil activating peptide (ENA)-78, gave similar data in
patients with CHF. IL-8 and GRO α showed a gradual increase parallel
to increasing NYHA class, in addition there was an inverse correlation
between IL-8 and left ventricular ejection fraction and cardiac index
(7). Thus chemokines seem to be important mediators in the persistent
immune activation observed in CHF patients, by activating circulating
neutrophils, T-cells, and monocytes and possibly by recruiting these
cells into the failing myocardium.
Autoantibodies
Antibodies against myocardial proteins were detected in 46% of
patients with dilated cardiomyopathy suggesting an autoimmune
involvement in dilated cardiomyopathy (52). The fact that organ-
specific cardiac antibodies were observed also in healthy asymptom-
atic relatives of patients with dilated cardiomyopathy (53), provides
evidence that they are not induced by myocardial injury and their mea-
surement might be useful for familial screening (54).
Autoantibodies against human beta-adrenergic receptors have also
been observed in in approx 25% of patients with cardiomyopathy and
were associated with a significantly poorer left ventricular function
(55,56). These autoantibodies can have widely differing allosteric effects
ranging from inhibitory to agonist-promoting activities; however, they
are associated with severe cardiac dysfunction (57). The elimination
of autoantibodies directed against beta-adrenergic receptors using
immunoadsorbtion techniques, and eventual IgG substitution seemed
to improve symptoms and cardiac performance in dilated cardiomy-
opathy (58–60).
Adhesion Molecules
Adhesion molecules mediate the interaction between endothelial
cells and circulating leukocytes (61,62). There are three general classes
of adhesion molecules on leukocytes and endothelium: integrins
(CD11a,b,c/CD18), selectins (platelet selectin [P-selectin], and endo-
thelial selectin [E-selectin]), and members of the immunoglobulin
superfamily of cell surface proteins (intercellular adhesion molecule-1
[ICAM-1] and vascular cell adhesion molecule-1 [VCAM-1]) (63). In
response to cytokines such as TNF-α, endothelial cells sequentially
express different adhesion molecules that preferentially bind different
leukocytes, inducing them to infiltrate tissues (64,65). In CHF the
expression of adhesion molecules by TNF-α is upregulated, and this
may cause the infiltration of mononuclear cells into the myocardium
(61,66). Upregulation of adhesion molecules such as ICAM-1 and
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integrin CD11a/CD18, and the presence of macrophages expressing
TNF-α has in fact been described in the myocardium of patients with
CHF (67). High plasma levels of soluble ICAM-1, which reflects
enhanced expression of the adhesion molecule on the cell surface, have
been observed in patients with CHF and correlated with the severity as
indicated by NYHA class, suggesting a possible prognostic role (68).
Other soluble adhesion molecules (VCAM-1, P-selectin, and E-selectin)
are also increased in CHF (69).
Complement System
Activation of the complement system may cause ventricular dam-
age or dysfunction through several mechanisms, including vasocon-
striction, ischemia, and apoptosis (70,71). Complement activation can
also contribute to cardiac injury through its effect on cytokine produc-
tion (72). Although the mechanisms of complement activation in CHF
are not known, significant activation of the complement system has
been seen in patients with symptomatic CHF and an association has
been observed between high levels of circulating terminal complement
complex (C5b-9) and near-term adverse events (73).
Endothelins
Endothelins (ET) are potent vasoconstrictor peptides released by
endothelial cells, expressed in four isoforms, ET-1, ET-2, ET-3, and
ET-4. Their production is stimulated by cytokines (74–77), vasopressor
hormones (78–80), thrombin, transforming growth factor-β (TGF-β)
(81), pulsatile and shearstress (82), and hypoxia (83–85), whereas
NO and prostacyclin reduce their expression (86). ET cause vasocon-
striction (87), cell proliferation (88), and myocardial effects through acti-
vation of endothelin A (ETA) receptors (89,90), but induce vasodilation
through the release of nitric oxide and prostacyclin by endothelial ETB
receptors (91).
ET-1, the main isoform in the human vasculature, is synthesized
from its precursor (big endothelin-1) through an endothelin-convert-
ing enzyme. As shown in experimental models, ET-1 is produced
within the myocardium when it is exposed to pathological stresses (92)
such as hemodynamic overload caused by aortic constriction (93,94), or
after myocardial infarction (95), and seems to mediate the process of
myocardial remodeling (96,97). The rise in ET-1 levels is due to an
increase in production (98), but the molecules stimulating this synthe-
sis are still unknown.
ET-1 has been evaluated in humans and its plasma levels of ET-1
were high in patients with CHF, correlated with the degree of pulmo-
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nary hypertension (99), and exercise impairment (100,101). ET-1 and its
precursor were related to both the magnitude of alterations in cardiac
hemodynamics and functional class severity of CHF and to the patient’s
prognosis (102,103).
The myocardium expresses both ETA and ETB receptors, and ETA
receptors are increased, when myocardium is exposed to hemodynamic
overload (99). Selective ETA and combined ETA-ETB antagonists have
been studied in patients with CHF, showing hemodynamic improve-
ment, i.e., reduced peripheral vascular and pulmonary resistence and
increased cardiac output (104).
Possible Causes of Immune Activation in Heart Failure
The origin of the immune activation in patients with CHF is still
unknown. Two hypotheses have been proposed on the basis of experi-
mental and clinical data. One suggests that the bowel wall edema leads
to bacterial translocation with subsequent endotoxin release and
immune activation (105). High endotoxin levels have been found in
CHF patients with peripheral edema (106). These endotoxin levels were
paralleled by elevated TNF-α levels. After 23 d diuretic treatment, there
was a fall in endotoxin levels but no change in TNF-α. Only after 41 d of
diuretic treatment was a small reduction of TNF-α seen. The authors
concluded that high plasma levels of cytokines in CHF patients were
due to the venous congestion, which can alter gut permeability for bac-
terial endotoxin, which can then be released into the circulation and
bind to CD14 receptors, mainly expressed on monocytes and tissue
macrophages, raising the synthesis of TNF.
The second suggestion is that the heart is the main source of
cytokines, as shown by the fact that TNF-α is produced by the failing
myocardium but not by a normal one (107,108). Experimental proof of
myocardial production of TNF-α has been proved by the fact that, in
isolated cat heart, a high left ventricular distending pressure induced
myocardial expression of TNF-α (109).
No single source of cytokine production (gut or heart) seems suffi-
cient to fully explain the multiple organ involvement and the systemic
inflammation of CHF, which also have been related to systemic hypoxia
(110). Hypoxia can be a potent stimulus for activation of the immune
system and for cytokine production (111,112). Figure 1 illustrates the
main hypotheses of immune activation in CHF.
Chf Therapies and the Immune System
As the important role of the immune system in CHF becomes clear,
many drugs used routinely in clinical practice have been seen to have
anticytokine effects.
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Beta-Blockers
From the 1970s to 1990s, there were some reports that proved beta-
blocker were effective in some patients with CHF, but the exact mecha-
nism of action is still not known. One potential link is the effect of the
sympathetic nervous system on immune function. Sympathetic over-
activity might lead to immune alterations that contribute to progres-
sion of left ventricular dysfunction in the presence of heart failure (113).
In patients with CHF of either ischemic or idiopathic etiology, meto-
prolol treatment improved cell-mediated immunity, especially the
response to skin tests, and correlated with changes in ejection fraction.
Additionally, there was increases in the natural killer (NK) cell popula-
tion and in T-suppressor/cytotoxic cells; the authors concluded that
the clinical improvement in patients taking beta-blockers may partly
Fig. 1. The main potential pathways of immune activation in congestive heart
failure. The edematous bowel wall facilitates entrance of the endotoxin into the
circulation, stimulating the secretion of cytokines by leukocytes/macrophages
and the failing myocardium. The cytokines then trigger immune activation, with
deleterious effects on the myocardium. Cytokines can also be produced by the
failing heart, setting a vicious circle between the heart and immune system
activation. Hypoxia may contribute to the increase of cytokine production.
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due to a blockade of sympathetic-induced immune abnormalities and
that, if this is the case, further investigation into the role of immuno-
logically mediated progression of left ventricular dysfunction is indi-
cated (113).
A recent study in patients with idiopathic dilated cardiomyopathy
noted significant reductions in serum levels of IL-10, TNF-α, and sTNF-
R2 after beta-blockers were added to their therapies (digitalis, diuret-
ics, and angiotensin-converting enzyme inhibitors) for 12 wk (114).
Another study suggested that metoprolol treatment in CHF is associ-
ated with a significant but temporary decrease in IL-2 receptors after
3 mo, possibly reflecting downmodulation of T-cell activation. How-
ever, enhanced immune activation also persisted in the metoprolol
group, suggesting a potential for more specific immunomodulatory
therapy (115).
Calcium Antagonists
The beneficial effect of amlodipine in CHF may be due to a reduc-
tion of cytokines such as IL-6, since in patients with CHF of NYHA III
and IV amlodipine for 26 wk lowered plasma IL-6 levels significantly
(116). There was no decrease of TNF-α. Adverse events or death were
more common among patients with higher IL-6 levels.
Angiotensin-Converting Enzyme (ACE) Inhibitors
and Angiotensin II Receptor Antagonists
ACE-inhibitors have favorable effects on mortality, morbidity
(117), and ventricular remodeling (118) in CHF. They cause hemody-
namic effects by reducing angiotensin II in plasma and tissue, raising
the concentration of bradykinin or NO and inhibiting the sympathetic
nervous system. Since certain ACE-inhibitors suppress IL-1 and TNF
synthesis in vitro, probably at a post-transcriptional level (119), investi-
gators have aimed to find out whether the ACE inhibitors also inhibit
immune activation in CHF.
In patients with severe CHF, high-dose enalapril was associated
with a significant decrease in IL-6 activity, but did not lower the levels
of other immunological parameters (IL-1ß, IL-1Ra, TNF-α, sTNF recep-
tors), which were all significantly high at baseline, reflecting persistent
immune activation in CHF (120). In other studies, ACE-inhibitors alone
(121), or combined with milrinone (122), were associated with lower
plasma TNF-α levels. ACE-inhibitors also suppressed lipopolysaccha-
ride (LPS)-induced production of TNF-α in vitro and in vivo (123). High
concentrations of captopril or valsartan had potent inhibitory effects
on LPS-stimulated production of TNF and IL-1 in vitro, by increasing
the anti-inflammatory cytokine IL-1Ra (captopril) and reducing IL-6
production (valsartan) (124). Long-term treatment with an angiotensin
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II type 1 receptor antagonist (candersartan cilexetil for 14 wk) signifi-
cantly reduced plasma markers of immune activation (TNF-α, IL-6) in
patients with mild to moderate CHF (125).
Phosphodiesterase Inhibitors
Phosphodiesterase inhibitors such as amrinone, pimobendan, or
vesnarinone, increase cAMP-mediated signaling in cardiac myocytes,
producing beneficial effects in patients with heart failure (126). How-
ever, clinical trials have shown that chronic treatment with these drugs
adversely affects survival (127). Phosphodiesterase inhibitors stop the
production of proinflammatory cytokines in patients with CHF (128)
and in experimental models (129). However, it is not clear whether this
anticytokine effect improves cardiac function and clinical symptoms.
New Approaches
Specific anti-cytokine compounds have now been introduced for
the management of CHF. Soluble TNF binding proteins (TNF-BP) were
sufficient to prevent, and even reverse, the negative inotropic proper-
ties of TNF-α in isolated contracting cardiac myocytes. The TNF-BP that
was most effective in blocking the negative inotropic effects of TNF-α
was sTNFR:Fc (130). This is a dimer of two extracellular domains of
TNFR2 (p75) fused in duplicate to the Fc portion of the human IgG1
molecule. A further study found that a single infusion of TNFR:Fc
antagonized the negative inotropic effects of chronic TNF-α infusion in
rats after 24 h (21). In transgenic mice overexpressing TNF, the analo-
gous soluble TNF receptor prevented myocardial inflammation, block-
ing the expression of adhesion molecules and cytokines, and reduced
left ventricular end-systolic diameter but not hypertrophy (131). Addi-
tional studies performed by the same group reported the ability of anti-
TNF therapy to modulate myocardial extracellular matrix remodeling
and to partially reverse pathological cardiac changes in the transgenic
murine model (132,133).
In a pilot study, a single intravenous infusion of a soluble p75 TNF
receptor fusion protein (Enbrel, etanercept), in patients with NYHA
class III heart failure, reduced TNF bioactivity and produced a signifi-
cant overall increase in quality-of-life scores, 6-min walk distance, and
ejection fraction (134). The same authors have now published the result
of 3 mo treatment with etanercept in patients with advanced heart fail-
ure, suggesting its safety and potential effectiveness in conjunction with
conventional therapies, although they analyzed only a limited number
of patients and for a short follow-up (135). Another group reported that
the administration of etanercept improved systemic endothelial vasodi-
lator capacity in patients with heart failure (136). On the other hand,
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preliminary results of an ongoing Phase II trial with infliximab in
patients with moderate to severe heart failure demonstrated higher
incidences of mortality and hospitalization for worsening heart failure,
especially with the highest dosages (137).
It has also been reported that intravenous immunoglobulins can
modulate the cytokine network in an antinflammatory direction; this is
significantly correlated with improvement of the left ventricular ejec-
tion fraction (138).
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